Table 1

Main performed investigations

First admissionOutpatientSecond admissionThird admission
From symptom onset2–3 weeks9–12 weeks13 weeks15 weeks
Haematology tests
Leucocytes (×109/L)10.812.46.9–10.010.6–13.0
Haemoglobin (g/L)7*710.710.98.2
MCV (fL)63.269.770.871.7
ESR (mm/hour)80
Biochemistry tests
CRP (mg/L) (N <3)137124–138243
Ferritin (ng/mL)146553541
Fe (µg/dL)142213
TSI (%)6.3–9.211.210.1
LDH (IU/L) (N 135–235)141–164
TSH (µU/mL)1.89
ANAs+ (citoplasmic pattern)
ENAs++
Anti-SSA Ab+++
ANCAs
C3 (mg/dL) (N 75–140)163151
Faeces
Calprotectin (ng/g) (N <30)2742411
Occult blood (×3)
UrinalysisNN
Microbiology tests
Serologies
Leishmania PCR
Blood, urine cultures
Stool cultureCampylobacter jejuni
IGRA
Clostridium difficile Ag
Image studies
Chest X-rayN
Abdominal ultrasoundN
EchocardiographyMild pericardial effussionMild pericardial effusion/aortic regurgitation
Gastrointestinal transitN
Abdominal CTN
Brain MRILeft maxillary sinusitisLeft maxillary sinusitis
Intestinal MRIThickening of the terminal ileum
MR angiographyInflammation of the wall of the thoracic and abdominal aorta and supra-aortic trunks
PET–CTIncrease in metabolism in thoracic and abdominal aorta
ColonoscopyMacroscopy: minimal changes in the terminal ileum
Microscopy: compatible with Crohn’s disease
  • *IV iron administered.

  • ANA, antinuclear antibody; ANCA, antineutrophil cytoplasmic antibody; CRP, C reactive protein; ENA, extractable nuclear antibody; ESR, erythrocyte sedimentation rate; IGRA, interferon-gamma release assay; LDH, lactate dehydrogenase; MCV, mean corpuscular volume; MR, magnetic resonance; N, normal; PET, positron emission tomography; TSH, thyroid-stimulating-hormone; TSI, transferrin saturation index.